Physician profile
Bruce S Morrison
NPI 1255449476
$45,287.42
in general payments reported to CMS, 2019-2025
55 companies · $8,042 in 2025
The $8,042 reported for 2025 was more than what 98% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,876 · 2020: $9,962 · 2021: $6,474 · 2022: $2,206 · 2023: $10K · 2024: $6,312 · 2025: $8,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $8,160 · Consulting Fee: $3,456 · Travel and Lodging: $1,644 · Education: $9.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,500.00 |
| Food and Beverage | $8,159.70 |
| Consulting Fee | $3,456.00 |
| Travel and Lodging | $1,643.77 |
| Education | $9.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20,101.64 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Allergan, INC. | $6,377.54 | 2019-2021 | |
| Abbvie INC. | $3,775.33 | 2021-2025 | |
| Astrazeneca Ab | $3,443.70 | 2020 | |
| Novo Nordisk INC | $1,209.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,039.86 | 2019-2025 | |
| Glaxosmithkline, LLC. | $966.10 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $953.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $833.21 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $822.30 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $811.57 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $542.28 | 2023-2025 | Sunosi, Auvelity |
| Amarin Pharma, INC. | $505.35 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.41 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $453.42 | 2022-2025 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.